Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific on Thursday reported a 5 percent increase in fourth quarter and full-year 2019 revenues.

The Waltham, Massachusetts-based company had Q4 revenues of $6.83 billion, up from $6.51 billion in Q4 2018 and beating the consensus analyst estimate of $6.78 billion. Organic revenue also grew 5 percent, while acquisitions drove revenue up by 1 percent and currency effects decreased revenue by 1 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.